↓ Skip to main content

A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis

Overview of attention for article published in BMC Neurology, November 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 X users
facebook
1 Facebook page

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
74 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis
Published in
BMC Neurology, November 2016
DOI 10.1186/s12883-016-0762-5
Pubmed ID
Authors

Raed Alroughani, Dirk Deleu, Khalid El Salem, Jasem Al-Hashel, K. John Alexander, Mohamed Assem Abdelrazek, Adel Aljishi, Jaber Alkhaboori, Faisal Al Azri, Nahida Al Zadjali, Majed Hbahbih, Tag Eldin Sokrab, Mohamed Said, Àlex Rovira

Abstract

Multiple sclerosis (MS) is a chronic autoimmune disease characterized by inflammatory and neurodegenerative processes leading to irreversible neurological impairment. Brain atrophy occurs early in the course of the disease at a rate greater than the general population. Brain volume loss (BVL) is associated with disability progression and cognitive impairment in patients with MS; hence its value as a potential target in monitoring and treating MS is discussed. A group of MS neurologists and neuro-radiologists reviewed the current literature on brain atrophy and discussed the challenges in assessing and implementing brain atrophy measurements in clinical practice. The panel used a voting system to reach a consensus and the votes were counted for the proposed set of questions for cognitive and brain atrophy assessments. The panel of experts was able to identify recent studies, which demonstrated the correlation between BVL and future worsening of disability and cognition. The current evidence revealed that reduction of BVL could be achieved with different disease-modifying therapies (DMTs). BVL provided a better treatment and monitoring strategy when it is combined to the composite measures of "no evidence of disease activity" (NEDA). The panel recommended a set of cognitive assessment tools and MRI methods and software applications that may help in capturing and measuring the underlying MS pathology with high degree of specificity. BVL was considered to be a useful measurement to longitudinally assess disease progression and cognitive function in patients with MS. Brain atrophy measurement was recommended to be incorporated into the concept of NEDA. Consequently, a consensus recommendation was reached in anticipation for implementation of the use of cognitive assessment and brain atrophy measurements on a regional level.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 1%
Unknown 73 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 18%
Student > Ph. D. Student 12 16%
Other 8 11%
Student > Postgraduate 7 9%
Professor 4 5%
Other 12 16%
Unknown 18 24%
Readers by discipline Count As %
Medicine and Dentistry 25 34%
Neuroscience 9 12%
Nursing and Health Professions 8 11%
Psychology 4 5%
Economics, Econometrics and Finance 2 3%
Other 6 8%
Unknown 20 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 February 2017.
All research outputs
#13,796,561
of 22,903,988 outputs
Outputs from BMC Neurology
#1,150
of 2,446 outputs
Outputs of similar age
#213,470
of 415,133 outputs
Outputs of similar age from BMC Neurology
#23
of 38 outputs
Altmetric has tracked 22,903,988 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,446 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 415,133 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.